Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(95)90104-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
WITHDRAWN: Vaccines for preventing malaria.
Cochrane Database Syst Rev
July 2007
EpiVec Consulting, 606 Kimberly Lane NE, Atlanta, GA 30306, USA.
Background: Four types of malaria vaccine, SPf66 and MSP/RESA vaccines (against the asexual stages of the Plasmodium parasite) and CS-NANP and RTS,S vaccines (against the sporozoite stages), have been tested in randomized controlled trials in endemic areas.
Objectives: To assess malaria vaccines against Plasmodium falciparum, P. vivax, P.
A rational strategy for a malarial vaccine development.
Microbes Infect
May 2007
Fundación Instituto de Inmunología de Colombia-FIDIC, Carrera 50 No. 26-00, Bogotá, Colombia.
Twenty years ago we reported the first synthetic peptide-based anti-malarial vaccine named SPf66, which conferred limited protective efficacy in large-scale human field-trials. Our efforts towards a second vaccine generation based on the rational selection of conserved high activity binding peptides (HABPs) whose critical binding residues have to be precisely replaced by others. Introducing peptide bond isosters on these HABPs' critical binding residues constitutes also an important approach.
View Article and Find Full Text PDFThe vaccine is dead--long live the vaccine.
Trends Parasitol
April 2007
Parasitologie Comparée et Modèles Expérimentaux, Centre National de la Recherche Scientifique IFR101, Muséum National d'Histoire Naturelle, 75231 Paris Cedex 05, France.
An important chapter in the search for a vaccine against malaria, that of the anti-Plasmodium falciparum vaccine candidate SPf66, has been effectively closed. A Cochrane review of ten major efficacy trials in endemic areas concluded it 'has little or no effect on preventing malaria'. This provides an appropriate opportunity to reflect on the perspectives for current and future vaccine formulations against Plasmodium.
View Article and Find Full Text PDFVaccines for preventing malaria (blood-stage).
Cochrane Database Syst Rev
October 2006
EpiVec Consulting, 606 Kimberly Lane NE, Atlanta, GA 30306, USA.
Background: A malaria vaccine is needed because of the heavy burden of mortality and morbidity due to this disease. This review describes the results of trials of blood (asexual)-stage vaccines. Several are under development, but only one (MSP/RESA, also known as Combination B) has been tested in randomized controlled trials.
View Article and Find Full Text PDFThe SPf66 Malaria Vaccine: What is the Evidence for Efficacy?
Parasitol Today
December 1998
Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!